ELMWOOD PARK, NJ, January 26, 2021 / PRNewswire / – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced COVID-19 testing agreements for players, officials, and team and league staff for the 2020-2021 season for the National Basketball Association ( NBA) and National Hockey League (NHL).
BioReference conducts COVID-19 testing for the NBA, NHL, United States soccer teams, Winter X Games, and NBA G League.
For the 2020-21 NBA season, BioReference is offering testing services with PCR and rapid diagnosis at 30 NBA team facilities in 28 cities across the United States. BioReference previously supported the restart of the 2019-20 NBA season.
Under an agreement with the NHL, BioReference will provide players, coaches, staff and officials with COVID-19 testing, including COVID-19 PCR laboratory diagnostics and rapid diagnosis, for the 24 US-based teams.
In addition, BioReference currently supports the Winter X Games in aspen, US football women’s and men’s national teams and the NBA G League in Orlando.
“Continuing to support the NBA through the 2020-21 season shows lessons Orlandoand uses new technology to support the current season and the overall partnership we have built during the COVID-19 pandemic, “he said Jon R. Cohen, MD, Executive Chairman of BioReference Laboratories. “Using similarly detailed and systematic protocols, we were selected to support the NHL, US football, the Winter X Games and the NBA G League. BioReference is privileged to support professional sport, which underscores our commitment to Develop bespoke solutions to help Americans. ” return to work safely and provide the nation with access to entertainment. “
About BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government agencies, correctional facilities, and medical groups. BioReference has developed and offers testing services that provide high quality and accurate results, including a molecular test to aid in COVID-19 diagnosis and a serological test to indicate possible COVID-19 exposure. The company is networked with the five largest health insurers The United States, operates a network of 11 laboratory locations and is supported by more than one medical staff 120 M..D., Ph.D. and other professional clinicians and scientists. With a leading position in genetics, women’s health, maternal fetal medicine, oncology and urology, BioReference and its specialist laboratories GenPath and GeneDx are driving the course of modern medicine. More information is available at www.bioreference.com.
About OPKO Health, Inc.
OPKO is a multinational biopharmaceuticals and diagnostics company committed to establishing industry-leading positions in large, fast-growing markets by leveraging its expertise in discovery, development, commercialization, and novel and proprietary technologies. More information is available at www.opko.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 (PSLRA). These statements can be identified by words such as “expected”, “plans”, “projects”. “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates” and other words of similar meanings, including statements about the role and value of tests, whether the results of our tests The previous testing program can be successfully duplicated or used in different environments or locations, regardless of whether the implementation of the same strategies or different strategies will prevent the spread of the disease or provide security against infection for participants, as well as other non-historical statements about our expectations, Beliefs or intentions about our business, technologies and products, and our strategies. Many factors could cause our actual activities or results to differ materially from those anticipated in any forward-looking statement. These factors include those described in OPKO Health, Inc.’s annual reports on Form 10-K, filed and filed with the Securities and Exchange Commission and its other filings with the Securities and Exchange Commission. In addition, forward-looking statements can be affected by general market factors, competitive product development, product availability, federal and state regulations and laws, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among others. The forward-looking statements contained in this press release speak only as of the date the statements are made, and we assume no obligation to update any forward-looking statements. We intend that all forward-looking statements be subject to the safe harbor provisions of the PSLRA.